This paper reports the results of a survey of human epidermal growth factor receptor 2 (HER2) and programmed death-ligand 1 (PD-L1) testing practices for gastric cancers in Japan. Survey data were used to identify potential associations between HER2 and PD-L1 score distribution and fixative type, fixation duration, cold ischemia time, testing kit and institutional factors for both surgical and biopsy specimens.
Nationwide survey on HER2 and PD-L1 testing practices in gastric cancer across Japan.
Abe H, Ushiku T, Kushima R, Kuwata T
Purpose
Conclusion
Surgical specimens fixed for >2 days had a lower percentage of HER2 3+ specimens and a higher percentage of HER2 0/1+ specimens than specimens fixed for ≤ 2 days (P=0.009 and P=0.046, respectively). HER2 scores were comparable between specimens fixed in 10% NBF and those fixed in other fixatives (all grouped) and between specimens with a cold ischemia time of <3 h versus ≥ 3h. Fixation duration, fixative type, and cold ischemia time did not affect PD-L1 scores in surgical specimens. HER2 and PD-L1 scores were comparable for biopsy specimens fixed in 10% NBF and those fixed in other fixatives (all grouped), specimens with a < 5 min versus ≥5 min cold ischemia time, and specimens fixed for < 24 h versus ≥ 24 h. There was a weak association between the institutional HER2 score distributions for biopsy and surgical specimens, such that those with a higher percentage of HER2-negative biopsy specimens also tended to have a higher percentage of HER2-negative surgical specimens. HER2 positivity did not differ between the HER2 detection kits evaluated or between institutions classified as an A or B by the Japanese Gastric Cancer Association (JGCA) based on the number of cases treated and number of specialists involved.
Studies (1)
Purpose
This study reports the results of a survey of HER2 and PD-L1 testing practices for gastric cancers in Japan. Survey data were used to identify potential associations between HER2 and PD-L1 score distribution and fixative type, fixation duration, cold ischemia time, testing kit and institutional factors for both surgical and biopsy specimens. A 10-question survey on HER2 and PD-L1 testing procedures was sent to 306 institutions certified by the Japanese Gastric Cancer Association (JCGAthe survey included questions to gauge if, when, where, and how HER2 and PD-L1 testing are performed; how many tests are performed annually; how test scores are reported; score distributions; and details of preanalytical handling including fixative type, fixation duration and cold ischemia times for both surgical and biopsy specimens. Statistical significance between variables was assessed using Fishers exact test and Welch’s t test.
Summary of Findings
Of the 155 responding institutions, 80 (52%) performed both PD-L1 and HER2 testing before chemotherapy, 49 (32%) only performed the HER2 test and 24 (15%) conducted the PD-L1 test only for HER2 negative cases. Among institutions that performed the tests, the median number of PD-L1 tests per year was significantly lower than the median number of HER2 tests performed per year (12 versus 31, P<0.001). The HER2 test was performed in-house by 88% of laboratories, with most using the Roche Ventana ultraView Pathway HER2 Kit (108 of 155, 70%) or the Agilent Dako HercepTest II (24 of 155, 15%). In contrast, PD-L1 testing was only performed in-house by 20 institutions (13%). Biopsy and surgical specimens were fixed in 10% NBF at the majority of institutions (95% and 91%, respectively), with the remaining institutions using 15% or 20% NBF or 10, 15 or 20% formalin. While 78% of institutions fixed biopsy specimens within 5 min of collection and 84% of institutions fixed biopsies for < 24, the delay to fixation for biopsy specimens was >30 min at 6% of institutions. For surgical specimens, 87% of institutions reported the time from resection to fixation as <3 h and 81% reported the fixation duration as < 2 days, but 21% were able to achieve a cold ischemia time of <60 min. The distribution of HER2 and PD-L1 scores and positivity for both biopsy and surgical specimen varied considerably among the responding institutions, and these differences were observed even when limited to institutions performing >20 tests per year.
Surgical specimens fixed for >2 days had a lower percentage of HER2 3+ specimens and a higher percentage of HER2 0/1+ specimens than specimens fixed for ≤ 2 days (P=0.009 and P=0.046, respectively); HER2 scores were comparable between specimens fixed in 10% NBF and those fixed in other fixatives (all grouped) and between specimens with a cold ischemia time of <3 h versus ≥ 3 h. Fixation duration, fixative type, and cold ischemia time did not affect PD-L1 scores in surgical specimens. HER2 and PD-L1 scores were comparable among biopsy specimens fixed in 10% NBF and those fixed in other fixatives (all grouped), specimens with a < 5 min versus ≥5 min cold ischemia time, and specimens fixed for < 24 h versus ≥ 24 h. There was a weak association between institutional HER2 score distributions for biopsy and surgical specimens (r=0.24-0.31), such that those with a higher percentage of HER2-negative biopsy specimens also tended to have a higher percentage of HER2-negative surgical specimens. HER2 positivity did not differ between the HER2 kits evaluated or between institutions classified as an A or B by the JGCA based on the number of cases treated and number of specialists involved.
Biospecimens
TissueStomachPreservation Types
FormalinDiagnoses
NeoplasticCarcinomaPlatforms
ProteinImmunohistochemistryPre-analytical Factors
Classification Pre-Analytical Factor Value(s) Biospecimen Acquisition Cold ischemia time <3 h versus ≥ 3h (surgical)<5 min versus ≥ 5 min (biopsy)Biospecimen Acquisition Method of tissue acquisition BiopsySurgical resectionBiospecimen Preservation Concentration of fixative 10%15% or 20%Biospecimen Preservation Time in fixative <24 h versus ≥ 24h (biopsy)≤ 2 days versus > 2 days (surgical)Biospecimen Preservation Type of fixation/preservation Formalin (buffered)Formalin (unbuffered)Immunohistochemistry Specific Targeted peptide/protein HER2PD-L1Immunohistochemistry Specific Technology platform Agilent Dako HercepTest IIRoche Ventana ultraView Pathway HER2 Kit